48 results about "Polyglutamate" patented technology

The invention discloses a bullfrog extracted biological collagen composition and a preparation method thereof in the technical field of collagen. The bullfrog extracted biological collagen composition comprises the following components in parts by weight: 1-1.5 parts of hydrophobic bullfrog source collagen peptide, 0.6-0.8 part of hydrophobic bullfrog source elastin peptide, 1-1.5 parts of polyglutamic acid and 1-1.5 parts of polylysine. Collagen and elastin in bullfrog skin and bullfrog cartilage are extracted in a combined mode through a three-enzyme co-production method, and after bullfrog source collagen peptide and bullfrog source elastin peptide are subjected to hydrophobic modification, polyglutamic acid and polylysine are added to form a collagen combination. The stability, the medicine carrying capacity and the slow release capacity of the composition can be improved.

The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with alpha or D-gamma polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with alpha or D-gamma polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with alpha or D-gamma polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

The application discloses a kind of compound fertilizer with nitrogen fertilizer slow-release and biocontrol function and preparation method, it is related to microbial compound fertilizer field, including the following components: nitrogen source carrier, physical net trapping material, 3,4-dimethyl pyrazole phosphate, biocontrol component, binder.A kind of preparation method, including the following steps: after silanization modification treatment is carried out to attapulgite, with polyglutamic acid aqueous solution mixed reaction, obtain self-assembly gel;Bacillus subtilis is embedded and handled, rhamnolipid is pre-emulsified, chitosan oligosaccharide is crosslinked with boric acid treatment, and is blended;Nitrogen source carrier is heated to melt, add self-assembly gel, mix evenly;Temperature control, add 3,4-dimethyl pyrazole phosphate, and keep warm reaction;Cooling, add the blend obtained in step S200, binder, mix evenly;Extrusion granulation, after fluidized bed drying, slow-release coating is carried out, and the target compound fertilizer is obtained.The application makes disease control efficiency to improve to 89.2%, and blocks nitrosomonas AMO enzyme activity for 120 days.

The invention provides a simple and rapid preparation method of a novel HER2 targeted nano-drug maytansine (DM1). The preparation of the nano-drug is realized by using carboxyl on a side chain of azide-terminated poly (L-glutamic acid) (PLG) as a load binding site. The preparation method comprises the following steps: firstly, grafting N-(2-aminoethyl) maleimide hydrochloride (Mal-C2H4-NH2-HCL) to carboxyl of PLG (Poly L-Glycol), and introducing a maleimide group to form PLG-Mal; the preparation method comprises the following steps: preparing Fc-III-4C peptide-PLG-Mal (Fc-PLG-Mal) by virtue of an amidation reaction between carboxyl and amino of the Fc-III-4C peptide, and then carrying out thiol-maleimide click chemical reaction on a maleimide group and sulfydryl of DM1, so as to obtain the Fc-PLG-DM1. Finally, the HER2 antibody and the Fc-PLG-DM1 are mixed in water by utilizing the high affinity effect between the Fc-III-4C peptide and the Fc segment of the HER2 antibody, so that the HER2-PLG-DM1 can be obtained, and the HER2-PLG-DM1 has a remarkable tumor inhibition effect in animal experiments. The successful development of the HER2-PLG-DM1 proves the potential of the method in the design and development of functional nano-drugs in the future.

The invention discloses a kind of sodium polyglutamate and the use of polyglutamic acid hydrogel with long-term moisturizing and skin-lightening, and belongs to the field of cosmetic technology. The preparation method of the sodium polyglutamate comprises the following steps: taking poly-L-glutamic acid, ε-polylysine, cyclo(glutamic acid-glutamic acid), 0.1mol / L MES / sodium chloride buffer solution, mixing, stirring for 3-4h, adding carbodiimide hydrochloride, continuing stirring for 1-2h, freezing at 0℃ for 6-8h, and obtaining the sodium polyglutamate; using the sodium polyglutamate to prepare a polyglutamic acid hydrogel with long-term moisturizing and skin-lightening effect.

In one aspect, a method of treating an NK cell to induce a gene edit. The method may include contacting an NK cell with a transfection composition including poly-L-glutamic acid (y- PGA), a single-stranded oligo deoxynucleotide (ssODN) enhancer, or a combination thereof; contacting the NK cell with an editing composition including: a DNA-PK inhibitor, and an HD AC inhibitor; electroporating the NK cell; and contacting the NK cell with a recovery composition including DNase I. In another aspect, a method of preparing an engineered NK cell comprising a fluorescent reporter at an endogenous locus. In another aspect, a method of treating an NK cell to introduce an exogenous nucleic acid.

The invention relates to a composite flocculant and a preparation method thereof. The preparation method of the composite flocculant comprises the following steps: carrying out surface modification on nano silicon dioxide by using a methacryloyloxy silane coupling agent to obtain modified nano silicon dioxide; polymerizing chitosan and polyglutamic acid to obtain a first copolymer; modifying the first copolymer by using glycidyl methacrylate to obtain a second copolymer; polymerizing the modified nano silicon dioxide and the second copolymer to obtain the composite flocculant. The composite flocculant has the advantages of high charge density of an inorganic phase and long-chain adsorption of an organic phase, the flocculation efficiency can be jointly improved through double mechanisms of chemical chelation and physical adsorption, and the composite flocculant has a relatively high biodegradation rate, is environment-friendly and has a good application prospect.

The present invention relates to a reprogramming responsive intelligent hydrogel material and a preparation method and application thereof. The hydrogel material provided by the present invention uses alginate as a skeleton, and uses RGD series polypeptides and polyglutamic acid to modify the skeleton respectively. The iPS cell line obtained by using the hydrogel material provided by the present invention to mediate somatic cell reprogramming is similar to embryonic stem cells, showing high expression of pluripotency-related genes at the transcriptional level and translational level, strong positive staining of alkaline phosphatase, and demethylation patterns of promoter regions of endogenous pluripotency-related genes Oct4 and Nanog. The hydrogel material provided by the present invention can quickly and efficiently obtain individual-specific induced pluripotent stem cells, laying a foundation for the acquisition of individual-specific induced pluripotent stem cells and their wide application in the fields of regenerative medicine, disease simulation and drug screening.

The invention provides a preparation method of HER2 targeted composite nanoparticles conjugated with a blood vessel disrupting agent, which comprises the following steps: grafting water-soluble azide-terminated poly (L-glutamic acid) with methoxy polyethylene glycol (NPLG-g-mPEG) to increase the number of effective load binding sites, bonding a cytotoxic drug SN38 with NPLG-g-mPEG through Steglich esterification reaction to obtain N3-PLG-SN38, and then adding the N3-PLG-SN38 into the HER2 targeted composite nanoparticles conjugated with the blood vessel disrupting agent to obtain the HER2 targeted composite nanoparticles conjugated with the blood vessel disrupting agent. According to the present invention, the Fc-PLG-SN38 is obtained by carrying out click chemical bonding on the Fc-III-4C peptide and the N3-PLG-SN38, by using the high affinity between the Fc-III-4C peptide and the Fc of the HER2 antibody, the antibody and the Fc-NPLG-SN38 are mixed in the water environment so as to obtain the HER2-PLG-SN38, and the HER2-PLG-SN38 and the blood vessel disrupting agent CA4P are conjugated so as to enhance the penetrating power and the drug effect on tumor cells;

The disclosure relates generally to alpha polyglutamated pralatrexate, formulations containing liposomes filled with alpha polyglutamated pralatrexate, methods of making the alpha polyglutamated pralatrexate and liposome containing formulations, and methods of using polyglutamated alpha polyglutamated pralatrexate and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

The disclosure relates generally to alpha polyglutamated aminopterin, formulations containing liposomes filled with alpha polyglutamated aminopterin, methods of making the alpha polyglutamated aminopterin and liposome containing formulations, and methods of using polyglutamated alpha polyglutamated aminopterin and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

The disclosure relates generally to polyglutamated alpha tetrahydrofolate compositions, including delivery vehicles such as liposomes containing the polyglutamated alpha tetrahydrofolate, and methods of making and using the polyglutamated alpha tetrahydrofolate compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis). The disclosed compositions also have uses in combination therapy with one or more therapeutic agents to enhance the effectiveness or to reduce the toxicities associated with the therapeutic agent(s).

The invention relates to a high-water-solubility denitroflavin-polyglutamic acid compound as well as a preparation method and application thereof, and belongs to the technical field of denitroflavin. The method comprises the following steps: adding the second generation of denitroflavin into an activated sodium polyglutamate solution, adjusting the pH value to 6.8-7.2, then stirring and reacting for 4-6 hours under the water bath condition of 45-55 DEG C, and dialyzing, freeze-drying and grinding to obtain the denitroflavin-polyglutamic acid compound. According to the preparation method, the water solubility of the second generation of denitroflavin is improved by cross-linking the second generation of denitroflavin and sodium polyglutamate for the first time, specifically, the second generation of denitroflavin is added into an activated sodium polyglutamate solution, so that free carboxyl of a side chain of the sodium polyglutamate and active groups of the second generation of denitroflavin are subjected to affinity reaction and multiple cross-linking; a stable three-dimensional network structure is formed, and the second-generation denitrioxanthin is wrapped in the sodium polyglutamate, so that the physical property of the second-generation denitrioxanthin is fundamentally changed to improve the water solubility of the second-generation denitrioxanthin.

This invention discloses a method for preparing passion fruit whole-fruit wine with improved clarification, belonging to the field of food processing technology. In this method, pectinase, cellulase, and transglutaminase are added before fermentation, and polyglutamic acid, bentonite, and curdlan are added after fermentation. The passion fruit whole-fruit wine obtained by this method has a light transmittance as high as 98.9%. The passion fruit wine composite clarifying agent prepared by this invention can be used in the preparation of passion fruit wine from whole passion fruit, significantly improving the clarity of passion fruit wine, reducing the technical difficulty and production cost of the clarification process, shortening the clarification time, effectively maintaining the flavor and nutritional value of the fruit wine, and improving the production efficiency of the fruit wine; it is simple to operate, easy to implement, and worthy of promotion and use.

The disclosure relates generally to alpha polyglutamated raltitrexed, formulations containing liposomes filled with alpha polyglutamated raltitrexed, methods of making the alpha polyglutamated raltitrexed and liposome containing formulations, and methods of using polyglutamated alpha polyglutamated raltitrexed and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

The disclosure relates generally to alpha polyglutamated aminopterin, formulations containing liposomes filled with alpha polyglutamated aminopterin, methods of making the alpha polyglutamated aminopterin and liposome containing formulations, and methods of using polyglutamated alpha polyglutamated aminopterin and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

The disclosure relates generally to polyglutamated alpha tetrahydrofolate compositions, including delivery vehicles such as liposomes containing the polyglutamated alpha tetrahydrofolate, and methods of making and using the polyglutamated alpha tetrahydrofolate compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis). The disclosed compositions also have uses in combination therapy with one or more therapeutic agents to enhance the effectiveness or to reduce the toxicities associated with the therapeutic agent(s).

The disclosure relates generally to alpha polyglutamated lometrexol, formulations containing liposomes filled with alpha polyglutamated lometrexol, methods of making the alpha polyglutamated lometrexol and liposome containing formulations, and methods of using polyglutamated alpha polyglutamated lometrexol and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

The invention relates to a temperature / pH dual-response type sodium polyglutamate-hyaluronic acid composite microsphere as well as a preparation method and application thereof, and belongs to the technical field of beauty medicines. Comprising the following steps: (1) mixing a polylactic acid-glycolic acid copolymer, poly (N-isopropylacrylamide) and chitosan to obtain a compound oil phase; (2) mixing polyglutamic acid, hyaluronic acid and RGD-PEG to obtain a functional water phase; (3) mixing the composite oil phase and the functional water phase to obtain W / O / W emulsion; and (4) carrying out selective crosslinking on the W / O / W emulsion, and then carrying out deep crosslinking to obtain the composite microspheres. The composite microsphere prepared by the invention has a temperature / pH double-response function, can shrink and release the active pharmaceutical ingredients in a skin inflammation high-temperature area after loading the active pharmaceutical ingredients, and also can accelerate degradation and release the active pharmaceutical ingredients in a weak acid environment.

To provide a gamma-polyglutamate oxidase folate antagonist composition that can overcome pharmacological challenges related to dose-limiting toxicity and therapeutic resistance associated with folate antagonist therapy. [Solution] A liposome composition (Lp-γPANTIFOL composition) containing a gamma polyglutamine oxidized folate antimetabolitic agent, wherein the gamma polyglutamine oxidized folate antimetabolitic agent contains 2 to 15 glutamyl groups, and the liposomes are pegylated.

The present invention provides a drug-loaded polyglutamic acid-based hydrogel and a preparation method thereof. The preparation method of the drug-loaded polyglutamic acid-based hydrogel provided by the present invention comprises the following steps: a) dissolving polyglutamic acid in water to obtain a polyglutamic acid solution; b) dissolving colcemid powder in an organic solvent to obtain a colcemid solution; c) dissolving polylysine in water to obtain a polylysine solution; d) mixing the polyglutamic acid solution, the colcemid solution and the polylysine solution, and standing to obtain a drug-loaded polyglutamic acid-based hydrogel; wherein, step a), step b) and step c) have no order restrictions. The drug-loaded polyglutamic acid-based hydrogel provided by the present invention can effectively improve the compressive strength and water retention rate of the material, and produce good antibacterial and anticancer abilities.

The present disclosure relates generally to polyglutamic acid-modified antifolate agents, formulations containing liposomes filled with alpha or D-gamma polyglutamic acid-modified antifolate agents, methods of making polyglutamic acid-modified antifolate agents and liposomal-containing formulations, and methods of treating myeloproliferative disorders (e.g., cancer) and immune system disorders (e.g., autoimmune diseases, such as rheumatoid arthritis) using the polyglutamic acid-modified antifolate and the liposomal-containing formulations.

The present application relates to the technical field of adhesive, in particular to an adhesive, a preparation method thereof and a self-adhesive flexible electrode. Sodium polyglutamate is dissolved in water to obtain a first solution. A modifying agent is dissolved in water to obtain a second solution, so that the modifying agent dissociates to form halogen ions and modifying ions, the modifying ions include N + groups connected with three substituents, and the group at the distal end is a long-chain alkyl with a chain length greater than or equal to 8. The first solution and the second solution are mixed, the precipitate is collected and dried to obtain an adhesive substance. The adhesive substance forms a viscous layer and is compounded with a flexible and conductive electrode layer to form a self-adhesive flexible electrode. Since polyglutamic acid has high biocompatibility, the N + group has a sterilization effect, and the long-chain alkyl has a hydrophobic effect, the adhesive has good biological affinity, antibacterial property and waterproof property, and also has strong adhesive capacity, which facilitates the stable adhesion of the self-adhesive flexible electrode to the skin surface, does not damage the skin and accurately outputs bioelectric signals.

This invention relates to the field of balloon technology, and discloses a functional balloon, its preparation method, and its application. The surface of the functional balloon is loaded with polyglutamic acid, which is linked to a DNA hydrogel via amide bonds. A nucleotide sequence is linked to the DNA hydrogel and thrombin. The balloon obtained by this invention can achieve hemostasis and reduce bleeding symptoms without vascular occlusion.

The present invention relates to a γ-polyglutamate degrading enzyme mutant and its application in preparing small molecule γ-polyglutamate. The amino acid sequence of the γ-polyglutamate degrading enzyme mutant is shown in SEQ ID NO.2, and the nucleotide sequence of the encoding gene is shown in SEQ ID NO.1. The present invention also provides a method for preparing small molecule γ-polyglutamate using the above-mentioned γ-polyglutamate degrading enzyme mutant. The present invention is based on polyglutamate degrading enzyme pgds, constructs a mutant library, and screens to obtain a γ-polyglutamate degrading enzyme mutant in which the isoleucine (Ile) at position 250 is mutated to serine (Ser) and the proline (Pro) at position 180 is mutated to cysteine ​​(Cys). Compared with polyglutamate degrading enzyme pgds, the enzyme activity of the γ-polyglutamate degrading enzyme mutant provided by the present invention is significantly improved, reaching 579.4U / mL, effectively increasing the activity of degrading γ-polyglutamate, and greatly improving the efficiency of degrading γ-polyglutamate.

The disclosure relates generally to gamma polyglutamated methotrexate compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated methotrexate, and methods of making and using the gamma polyglutamated methotrexate compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis).

The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with the polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using the polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

To provide alpha polyglutamated pemetrexed compositions to overcome pharmacological challenges related to dose limiting toxicities and treatment resistance associated with pemetrexed therapy.SOLUTION: Disclosed is a liposome composition comprising a liposome encapsulating alpha polyglutamated pemetrexed, where the alpha polyglutamated pemetrexed comprises 2-10 glutamyl groups having an alpha carboxyl group linkage, the liposome is PEGylated, and the liposome composition comprises a targeting moiety that has a specific affinity to a surface antigen on a target cell.SELECTED DRAWING: None